Simpler two-drug HIV treatment with dolutegravir and lamivudine
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial studies whether taking dolutegravir plus lamivudine (a simpler two-drug regimen) can work as well as a standard three-drug HIV regimen for people who have reasons they can’t stay on the usual medicines. You may be offered free treatment if you meet the safety checks and can attend follow-up visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re over 18 years old and can join the study in person
- You have HIV-1 infection
- You’ve been on a standard three-drug HIV regimen for at least 24 weeks
- Your clinic can monitor your CD4 blood count multiple times in the first year and then every 6 months
- You must be able to follow the study schedule and sign consent for free treatment
- You cannot be allergic to dolutegravir or lamivudine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether a simpler set of HIV medicines works for people with confirmed HIV-1 infection. It may help by making treatment easier to follow, while monitoring health with regular blood tests.
This trial tests whether switching (or continuing) treatment with dolutegravir (DTG) plus lamivudine (3TC) works as well and is better tolerated in adults with HIV that is already controlled. It is specifically for people who have possible kidney (TDF-related) or bone side effects from their current TDF-based regimen.
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
This study collects data from HIV patients who start treatment with a two-drug combination of dolutegravir and lamivudine, either as their first treatment or after switching from a three-drug regimen.
This trial studies a two-drug pill (DTG/3TC) for people who have never taken HIV medication before. It aims to see if this simpler treatment is effective and safe for controlling HIV-1.
Hear when a new HIV/AIDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.